Vesugen
Also known as Vesugen KED, KED tripeptide, Lys-Glu-Asp, lysyl-glutamyl-aspartic acid
Vesugen is a vascular-targeting peptide that penetrates endothelial cell membranes to activate Ki-67 and SIRT1 genes, upregulating longevity pathways and vascular regeneration signals while promoting collagen and elastin synthesis within blood vessel walls—achieving 53-61% improvements in vascular endothelial function and reversing age-related vascular stiffness through epigenetic gene expression modulation.
Route
Subcutaneous injection
Dose range
500 mcg – 2 mg
Frequency
Once per day (subcutaneous)
Cycle length
8–12 weeks
Overview
Vesugen is a vascular-targeting peptide that penetrates endothelial cell membranes to activate Ki-67 and SIRT1 genes, upregulating longevity pathways and vascular regeneration signals while promoting collagen and elastin synthesis within blood vessel walls—achieving 53-61% improvements in vascular endothelial function and reversing age-related vascular stiffness through epigenetic gene expression modulation.
Key mechanism involves direct DNA interaction within endothelial cells to stimulate genes controlling cellular repair, migration, angiogenesis, and vascular flexibility. Research shows improved blood vessel elasticity, enhanced endothelial function, and support for vascular healing without systemic effects characteristic of systemic vasodilators. Clinical applications span vascular aging reversal, endothelial dysfunction, atherosclerosis prevention, and cardiovascular resilience. For aging individuals with vascular stiffness, hypertension, or endothelial dysfunction, Vesugen offers direct vascular tissue rejuvenation through epigenetic restoration of youthful vascular function.
Studied benefits
- Targeted toward vascular health, this peptide may support the renewal of blood vessel linings (endothelial cells)
- Research in elderly patients suggests it may improve memory and attention while restoring synaptic health in the brain
Reported side effects
- Generally well-tolerated in early studies
- possible side effects are limited to mild, temporary itching or redness at the site of injection
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
Vesugen (20mg)
Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~6.67 mg/mL).
Support vascular endothelial function and support cellular renewal in the circulatory system.
| Week | Daily Dose (mcg) | Draw at 6.67 mg/mL | Log |
|---|---|---|---|
| Week 1 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) | + Log |
| Week 2 | 1000 mcg (1.0 mg) | 15 units (0.15 mL) | + Log |
| Week 3 | 1500 mcg (1.5 mg) | 22.5 units (0.225 mL) | + Log |
| Weeks 4–8+ | 1500–2000 mcg | 30 units (0.3 mL) | + Log |
Frequency
Once per day (subcutaneous).
Timing
Any consistent time; rotate injection sites.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
6.67 mg/mL
40 doses of 500 mcg per vial
At the starting dose (500 mcg × 7/week for a 8-week cycle) you would use about 28 mg, i.e. 2 × 20 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Maintain a diet rich in essential fatty acids and antioxidants to support the vascular endothelium and systemic circulation promoted by this bioregulator peptide. Engage in regular aerobic exercise to enhance blood flow and vascular elasticity, which works in harmony with the peptide’s goal of improving vessel wall integrity. Ensure 7–9 hours of quality sleep to facilitate the deep-repair phase of the cardiovascular system. Avoid smoking and highly processed foods, which generate oxidative stress and can damage the endothelial lining that the peptide seeks to protect and restore.
Evidence
Research summaries
Vesugen Peptide in Vascular Endothelial Protection and Anti-Aging
Findings: Strengthens blood vessel walls, improves flow to brain and heart, cuts risk of clots or hardening.
Vesugen targets endothelial cells (the lining inside blood vessels). In lab tests, it boosted genes like those for repair (e.g., influencing chromatin like Vesilute), making vessels less leaky and stiff. Animal models of aging showed 25% better blood flow in tiny brain pipes after weeks, reducing fog and tiredness. For heart health, it lowered bad inflammation markers (IL-6), easing chest pain in early clog studies. Simply: old vessels get crumbly; Vesugen glues them back, pumping oxygen better everywhere. Russian trials hinted at fewer angina attacks, with patients feeling warmer limbs. Safe profile, no drops in blood pressure oddly.
Read the study ↗Neuroprotective and Vasculogenic Effects of Vesugen in Atherosclerosis Models
Findings: Helps brain function by better blood delivery, supports erection health from vessel fixes, reduces stroke aftermath.
41 men with vessel-based erection issues got Vesugen; Doppler scans showed big jumps in penile artery flow, fixing the problem in most via cleared atherosclerosis. Brain-wise, post-stroke patients improved cognition scores by 22% likely from revived circulation. It repairs leaky barriers, cuts swelling (edema), fights low oxygen (hypoxia). Mechanism: tweaks vessel smooth muscles and genes for strength. For 9th graders: like clearing river dams so water (blood) reaches farms (organs) fully. Small but solid results, with calls for Western repeats.
Read the study ↗Vesugen in Chronic Arterial Issues and Elderly Vascular Health
Findings: Boosts leg circulation, eases walking pain, protects nerves tied to vessels.
In older adults with leg artery narrowness, 1mg/day Vesugen over months normalized brachial artery flow, dropped inflammation, and improved life quality. 48-person trial saw 24 better flows; another cut angina. It prevents sclerosis by calming overgrowth and boosts oxygen. Post-stroke group gained memory via brain vessel tweaks. Gentle on body, enhances microcirculation everywhere. Imagine tired legs from poor delivery—Vesugen restocks fuel lines.
Read the study ↗Geroprotective Role of Vesugen in Metabolic and Neural Resilience
Findings: Slows aging in vessels/brain, aids metabolic balance, supports overall vitality.
Vesugen influences fibroblasts and chemokines for vessel rebuild, neuroprotective against decline. Aging tests showed less hypoxia, better blood-brain shield. Erectile dysfunction trial confirmed vascular wins. Combines with anti-aging genes, potentially extending healthy years. Low doses effective, no toxicity—prime for longevity research. Vesugen is a three-part peptide (Lys-Glu-Asp, or KED) that acts like a tune-up for your blood vessels. Imagine vessels as highways carrying oxygen and food to every cell—if they clog or weaken with age, you feel tired, organs hurt, and risks like heart attacks rise. Vesugen research shows it cleans these highways, strengthens walls, and fights clots. Developed by Khavinson's team, it's studied for heart, brain, and eye health. Simple benefits: better energy, sharper mind, healthier eyes. Here's findings from PubMed/PMC-level sources, explained easy.
Read the study ↗Endothelial peptide bioregulator Vesugen in therapy of coronary heart disease
Findings: Clears vessel clogs, boosts heart blood flow, cuts chest pain and fatigue for active living.
Patients with coronary disease (narrowed heart arteries) got Vesugen courses. Angiograms showed 20-30% better vessel openness—peptide normalized endothelium (vessel lining cells), reducing plaques like scraping rust off pipes. Angina attacks dropped 70%, exercise tolerance up (walk farther without huffing). It ramps nitric oxide for dilation and cuts inflammation. Safe add-on to statins. Clinical edge: prevents bypasses, energizes seniors. Cycles restore vessel youth.
Read the study ↗Short peptide
More references (7)
- Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes (2024)
- Peptides Tissue-Specifically Stimulate Cell Differentiation During Their Aging (2022)
- Peptide Regulation of Gene Expression: A Systematic Review (2021)
- Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer's Disease (2021)
- Epigenetic Aspects of Peptidergic Regulation of Vascular Endothelial Cell Proliferation During Aging (2014)
- The Efficacy of Peptide Bioregulators of Vessels in Lower Limbs Chronic Arterial Insufficiency Treatment in Old and Elderly People (2014)
- CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 (2025)
Identification
Chemistry
- common names
- Vesugen, Vesugen KED, KED tripeptide, Lys-Glu-Asp, lysyl-glutamyl-aspartic acid, lysylglutamylaspartic acid, L-lysyl-L-glutamyl-L-aspartic acid, tripeptide bioregulator
- cas
- Not assigned (N/A); no official CAS registry number formally designated
- formula
- C₁₅H₂₆N₄O₈
- molecular weight
- 390.39 Da or g/mol
- source
- Synthetic; not naturally occurring as isolated tripeptide, though represents combination of amino acids present in vascular wall proteins and collagen
- biosynthesis
- Nonribosomal; synthesized via solid-phase peptide synthesis (SPPS) from purified L-lysine, L-glutamic acid, and L-aspartic acid monomers
- type
- Linear tripeptide with:
Keep exploring
Related peptides
ARA-290
ARA290 · Cibinetide
- Route
- Subcutaneous
- Dose
- 4 mg – 8 mg
- Cycle
- 4–8 weeks
B7-33
B7-33 peptide · RXFP1 agonist B7-33
- Route
- Subcutaneous
- Dose
- 150 mcg – 500 mcg
- Cycle
- 4–8 weeks for acute fibrosis studies
Bronchogen
AEDL · Ala-Glu-Asp-Leu peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days; often repeated every 4–6 months
Cardiogen
AEDR · Ala-Glu-Asp-Arg peptide
- Route
- Subcutaneous
- Dose
- 1 mg – 2 mg
- Cycle
- 10–20 days